{"id":533,"date":"2022-10-02T09:09:25","date_gmt":"2022-10-02T07:09:25","guid":{"rendered":"https:\/\/modafinil.pl\/sklep\/noopept-%d0%bd%d0%be%d0%be%d0%bf%d0%b5%d0%bf%d1%82-synthetic-substance-%e2%89%a5-99-1000mg\/"},"modified":"2026-09-30T07:33:27","modified_gmt":"2026-09-30T05:33:27","slug":"noopept-2","status":"publish","type":"product","link":"https:\/\/modafinil.pl\/en\/sklep\/noopept-2\/","title":{"rendered":"Noopept (CAS 157115-85-0) \u2014 laboratory reagent 1000 mg, purity \u2265 99%"},"content":{"rendered":"

N-Phenylacetyl-L-prolylglycine ethyl ester<\/strong> (development code GVS-111), crystalline powder, 1000 mg pack. Material intended exclusively for laboratory and analytical in vitro research<\/strong>. This product is not intended for human or animal consumption<\/strong>; it is not a medicinal product, food supplement, foodstuff or cosmetic.<\/p>\n

Three distinct entities that must not be confused<\/h2>\n

This molecule has an unusual feature: its common name (Noopept) is also the name under which the preparation appears in the Russian clinical literature. This makes it all the more necessary to separate the layers right at the outset:<\/p>\n\n\n\n\n\n\n\n
Separating the layers: substance \u2014 medicinal product \u2014 reagent<\/caption>\n
Entity<\/th>\nWhat it is<\/th>\nStatus of noopept<\/th>\n<\/tr>\n<\/thead>\n
Chemical substance
CAS 157115-85-0<\/th>\n		A chemical concept \u2014 a molecule of defined structure, registered in databases (PubChem CID 180496, ChEMBL CHEMBL3663392). The INN of this substance is omberacetam<\/strong>.<\/td>\na chemical concept; in itself neither a medicine nor a reagent<\/td>\n<\/tr>\n
Medicinal product
available in the Russian Federation<\/th>\n		The clinical publications cited in the literature [9][10][14] describe it explicitly as a \u201cnew nootropic drug\u201d (original English wording: new nootropic drug<\/em>) administered to patients in open-label studies, with EEG assessment and neuropsychological testing. It is precisely this entity \u2014 a registered pharmaceutical preparation \u2014 that the clinical studies involving humans concerned.<\/strong><\/td>\nexists as a pharmaceutical product in Russia; according to the international ChEMBL register the substance has Preclinical<\/em> status (max_phase 0), i.e. it has not gone through the Western registration pathway<\/td>\n<\/tr>\n
Chemical reagent
the material offered here<\/th>\n		Material for laboratory and analytical work. It does not have, and cannot have, any authorisation for use in humans or animals<\/strong> \u2014 it has no pharmaceutical form and no medicinal product documentation.<\/td>\nanalytics, chemistry, reference standards<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

The consequence is unambiguous.<\/strong> The research results referred to later on this page were obtained either with the pharmaceutical preparation available in Russia<\/strong> (clinical studies involving humans) or with the substance administered to laboratory animals or tested on cell cultures<\/strong> (preclinical studies). None of these studies was conducted with an analytical reagent<\/strong>, and none of these results transfers to the material offered.<\/p>\n

Reagent identification sheet<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Registry data and identifiers \u2014 noopept<\/caption>\n
Systematic name (IUPAC)<\/th>\nethyl 2-[[(2S)-1-(2-phenylacetyl)pyrrolidine-2-carbonyl]amino]acetate
(N-phenylacetyl-L-prolylglycine ethyl ester)<\/td>\n<\/tr>\n
INN<\/th>\nomberacetam<\/td>\n<\/tr>\n
Development code<\/th>\nGVS-111<\/td>\n<\/tr>\n
CAS number<\/th>\n157115-85-0<\/td>\n<\/tr>\n
Molecular formula<\/th>\nC17<\/sub>H22<\/sub>N2<\/sub>O4<\/sub><\/td>\n<\/tr>\n
Molar mass<\/th>\n318.4 g\u00b7mol\u22121<\/sup><\/td>\n<\/tr>\n
Monoisotopic mass<\/th>\n318.1580 Da<\/td>\n<\/tr>\n
InChIKey<\/th>\nPJNSMUBMSNAEEN-AWEZNQCLSA-N<\/td>\n<\/tr>\n
SMILES<\/th>\nCCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)CC2=CC=CC=C2<\/td>\n<\/tr>\n
PubChem CID<\/th>\n180496<\/a><\/td>\n<\/tr>\n
ChEMBL<\/th>\nCHEMBL3663392<\/td>\n<\/tr>\n
Form<\/th>\ncrystalline powder, white to off-white<\/td>\n<\/tr>\n
Purity<\/th>\n\u2265 99%<\/td>\n<\/tr>\n
Intended use<\/th>\nresearch reagent \u2014 not for human or animal consumption<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Origins of the molecule: rational dipeptide design<\/h2>\n

Noopept was not the product of a chance discovery, nor of trial-and-error modification of an existing drug. It is the outcome of a deliberate strategy for designing dipeptide drugs<\/strong>, developed at the V. V. Zakusov Institute of Pharmacology in Moscow. This strategy \u2014 described explicitly by its authors \u2014 consisted of isolating structural fragments (amino acid residues, peptide bonds) from the molecules of non-peptide drugs with known activity and then designing topologically similar peptide analogues [6]. In the literature, Noopept is consistently described as a dipeptide analogue of piracetam<\/strong> [1] \u2014 not its metabolite or a chemical derivative in the synthetic sense, but a molecule designed around the same pharmacophore fragment.<\/p>\n

A metabolite that is also a natural neuropeptide<\/h3>\n

Pharmacokinetic studies in rats showed that the compound undergoes enzymatic breakdown to three metabolites, one of which \u2014 cyclo-Pro-Gly<\/strong> (cyclo-L-prolylglycine, a diketopiperazine) \u2014 proved to be an active metabolite and at the same time a structure identical to an endogenous neuropeptide [1]. This relationship has an analytical consequence: cyclo-Pro-Gly is also observed as a product of intramolecular cyclisation in material of reduced purity, so an HPLC-UV method should separate it from the parent substance.<\/p>\n

Timeline<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Timeline: design, preclinical and clinical research<\/caption>\n
1997<\/th>\nfirst indexed pharmacokinetic studies of GVS-111 in rats; identification of the active metabolite cyclo-Pro-Gly [1]<\/td>\n<\/tr>\n
2000<\/th>\ndemonstration of neuroprotective properties in cell cultures (oxygen-glucose deprivation, glutamate toxicity) [2]<\/td>\n<\/tr>\n
2002<\/th>\nchronic toxicity study in rabbits [3]; basic electrophysiological studies on molluscan neurons [4]; prefrontal cortex lesion model in the rat [5]<\/td>\n<\/tr>\n
2003<\/th>\npublication of the strategy for designing dipeptide neuropsychotropic drugs \u2014 the rationale for the rational design of the molecule [6]<\/td>\n<\/tr>\n
2005\u20132007<\/th>\nseries of studies in animal models of Alzheimer’s disease (beta-amyloid administration) [7][8]<\/td>\n<\/tr>\n
2008\u20132011<\/th>\nclinical studies involving humans, using the pharmaceutical preparation available in Russia: post-traumatic and vascular cognitive disorders [9], comparison with piracetam [10], stroke [14]<\/td>\n<\/tr>\n
2010<\/th>\ndescription of the effect on inhibitory synaptic transmission in the hippocampus by the patch-clamp method [11]; studies of the molecular mechanism of action involving the Ufa centre [12]<\/td>\n<\/tr>\n
2011<\/th>\nstudy conducted outside Russia (Ume\u00e5 University, Sweden) on the effect on \u03b1-synuclein amyloid cytotoxicity [13]<\/td>\n<\/tr>\n
2013\u20132015<\/th>\nextension of research to a diabetic model [15]; continuation of the 2010 electrophysiological line by the same team [16]<\/td>\n<\/tr>\n
2018<\/th>\nreview of twenty years of the \u201cdipeptide drugs\u201d project by a co-author of the original molecular design [17]<\/td>\n<\/tr>\n
2020\u20132022<\/th>\nmolecular studies involving the Ufa centre on the transcription factor HIF-1 [18]; latest publication of the electrophysiological line from the Research Center of Neurology [19]<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

The centres that built the literature<\/h2>\n

As with other substances of Russian origin in our catalogue, the literature on noopept has a concentrated geography \u2014 three centres, each with its own research profile.<\/p>\n